AKAO 2017 Annual Report

149 POWER OF ATTORNEY KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints each of Blake Wise, Tobin C. Schilke and Gary Loeb his or her true and lawful attorney-in-fact and agent, with full power of substitution, for him or her and in his or her name, place and stead, in any and all capacities, to sign any and all amendments to this annual report on Form 10-K, and to file the same, with all exhibits thereto, and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorney-in-fact and agent, full power and authority to do and perform each and every act and thing requisite and necessary to be done in connection therewith, as fully to all intents and purposes as he might or could do in person, hereby ratifying and confirming all that said attorney-in-fact and agent, or his substitutes or substitute, may lawfully do or cause to be done by virtue hereof. IN WITNESS WHEREOF, each of the undersigned has executed this Power of Attorney as of the date indicated opposite his/her name. Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed by the following persons on behalf of the registrant and in the capacities and on the dates indicated. Signature Title Date /s/ Blake Wise Chief Executive Officer and Director February 27, 2018 Blake Wise ( Principal Executive Officer ) /s/ Tobin C. Schilke Chief Financial Officer February 27, 2018 Tobin C. Schilke ( Principal Financial and Accounting Officer ) /s/ Bryan E. Roberts Chairman of the Board of Directors February 27, 2018 Bryan E. Roberts, Ph.D. /s/ Karen Bernstein Director February 27, 2018 Karen Bernstein, Ph.D. /s/ John C. Doyle Director February 27, 2018 John C. Doyle /s/ Michael Fischbach Director February 27, 2018 Michael Fischbach, Ph.D. /s/ Kenneth J. Hillan President, R&D, President, Achaogen and Director February 27, 2018 Kenneth J. Hillan, M.B., Ch.B. /s/ Kent E. Lieginger Director February 27, 2018 Kent E. Lieginger, Pharm.D. /s/ John W. Smither Director February 27, 2018 John W. Smither /s/ Gregory Stea Director February 27, 2018 Gregory Stea /s/ Halley Gilbert Director February 27, 2018 Halley Gilbert